Prestige BioPharma Limited (KRX: 950210)

Market Cap	173.08B
Revenue (ttm)	2.84B
Net Income (ttm)	-29.59B
Shares Out	12.02M
EPS (ttm)	-490.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,741
Open	15,160
Previous Close	15,040
Day's Range	14,620 - 15,160
52-Week Range	7,610 - 20,900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Singapore
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 950210